Creatinine

Research presented at the virtual ASN Kidney Week suggested 30% of patients hospitalized with AKI received inadequate follow-up, with medical risk factors being the “primary determinants” of care after hospitalization.

Ultrafiltration for acute decompensated HF reduced hospital readmission by 1.74 visits in the following 12 months compared with the prior year, according to data presented at the virtual Heart Failure Society of America Scientific Meeting.

WASHINGTON — Researchers of a poster presented at ASN Kidney Week observed wide fluctuations in serum creatinine in patients with lupus nephritis in remission.

WASHINGTON — Ritonavir-boosted protease inhibitors do not significantly impact creatinine-based GFR estimates compared with measured GFR for HIV-positive patients, according to data presented at ASN Kidney Week.

SAN DIEGO — Early screening and early diagnosis are critical to managing systemic sclerosis, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Age appears to be “the most reliable and important risk factor” for mortality after lung transplantation among U.S. adults, according to data published in Chest.

PARIS — Inclisiran, an investigational cholesterol-lowering therapy in the small-interfering RNA class, achieved durable and potential LDL reduction with twice-yearly injections, according to new data from the ORION-11 study.

PARIS — Sacubitril/valsartan did not reduce the rate of hospitalizations for CV-related death and HF in patients with HF with preserved ejection fraction, defined as at least 45%, according to a hot line trial presented at the European Society of Cardiology Congress.

In patients with atrial fibrillation, or AF, treated with direct oral anticoagulants, standardized perioperative management approaches were tied to lower rates of bleeding and stroke, according to a study published in JAMA Internal Medicine.

Erdafitinib induced a high rate of objective tumor response in patients with locally advanced and unresectable or metastatic urothelial carcinoma with FGFR alterations, according to results of a single-arm phase 2 study published in The New England Journal of Medicine.